Canaccord Genuity Group Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price

TriSalus Life Sciences (NASDAQ:TLSI) had its price target lowered by Canaccord Genuity Group from $12.00 to $11.00 in a report published on Friday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research analysts have also weighed in on TLSI. Roth Mkm initiated coverage on shares of TriSalus Life Sciences in a research note on Monday, November 11th. They issued a “buy” rating and a $11.00 price target on the stock. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target on the stock. Roth Capital raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Oppenheimer assumed coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 target price on the stock. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $12.08.

TriSalus Life Sciences Stock Down 6.6 %

NASDAQ:TLSI opened at $3.67 on Friday. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42. The stock has a market capitalization of $111.90 million, a PE ratio of -1.47 and a beta of 0.49. The stock’s 50-day moving average price is $4.30 and its 200-day moving average price is $5.71.

Insider Activity

In other news, CEO Mary T. Szela purchased 7,520 shares of TriSalus Life Sciences stock in a transaction dated Thursday, September 12th. The shares were purchased at an average price of $5.20 per share, with a total value of $39,104.00. Following the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 2.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 32.80% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Institutional investors have recently made changes to their positions in the company. Walleye Capital LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at approximately $66,000. Vestcor Inc acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at approximately $108,000. MSD Partners L.P. acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at approximately $184,000. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences in the 2nd quarter valued at approximately $240,000. Finally, Geode Capital Management LLC increased its holdings in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after purchasing an additional 62,542 shares during the last quarter. Hedge funds and other institutional investors own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.